Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific personnel transaction rather than a financial performance report.
Material Changes
No material changes to financial performance or business operations are reported. The filing details a re-valuation of the cash element of a notional investment held within the US Retirement Savings Plan, resulting in an increase in the notional allocation of Ordinary share ADRs.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Important Facts for Investors
- Transaction Date: The notional allocation increase occurred on May 13, 2011.
- Price: The transaction price was $43.74 per ADR.
- Involved Parties: The transaction involved Dr. M M Slaoui (Director/PDMR) and Dr. K Slaoui (Connected Person).
- Volume: The transaction involved 4 ADRs.
- Context: The change resulted from a re-valuation of the cash element of the notional investment within the US Retirement Savings Plan.